Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

Дата публикации: 02-07-2026 21:20:06

For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with more meaningful reductions in hemoglobin A1C (HbA1c) levels than semaglutide, according to a study published online June 30 in the Annals of Internal Medicine.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Weight‑loss jabs may create a new kind of yo‑yo dieting	0	7	10-07-2026
2	Stanford researchers say your body already makes this Ozempic alternative	0	7	15-06-2026
3	Ученые выявили новый побочный эффект приема "Оземпика"	0	7	30-06-2026
4	Most obesity drugs do not improve quality of life or heart health, analysis indicates	-2	7	08-07-2026
5	New treatment helps achieve a healthier BMI in people with weight dysregulation after brain tumors	5	7	09-07-2026
6	GLP-1 'secret shopper' study finds gaps in online prescribing	0	5	07-07-2026
7	GLP-1 use hits record high as Medicare opens access to weight-loss drugs	0	7	09-07-2026
8	Societies combine to issue recommendations on use of incretin drugs in obesity therapy	0	7	09-07-2026
9	Diabetes drug for prostate cancer? Study provides clarity	0	7	08-11-2023
10	FDA advisory committee for peptides stocked with conflicts of interest	0	5	01-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: medicalxpress.com.